Polypharmacy with antidepressants in children and adolescents.

The aim of this study was to review current epidemiological data on the use of antidepressants in co-prescription with other psychotropic drugs in children and adolescents, as well as available efficacy and safety information. A Medline search from inception until February 2012 was performed to identify epidemiological and clinical studies, reviews and reports containing potentially relevant information on polypharmacy with antidepressants in young people. There has been an increase in polypharmacy in children and adolescents involving antidepressants in recent years. Antidepressants have become one of the drug classes most frequently prescribed in combination and are commonly co-prescribed with stimulants and antipsychotics. Most information regarding efficacy and safety of polypharmacy patterns was provided by case series and open-label studies. Efficacy studies gave some support for the use of a combination of antidepressants and antipsychotics in the management of refractory obsessive-compulsive disorder and some residual symptoms in major depressive disorder. Even less empirical support was found for a combination of stimulants and antidepressants in co-morbid attention deficit hyperactivity disorder and mood or anxiety disorders. Adverse events were similar to those found with individual medication groups, with severe adverse events mostly reported by individual case reports. The use of polypharmacy with antidepressants has become a regular practice in clinical settings. Although there is still little efficacy and safety information, preliminary evidence points to the potential clinical usefulness of some polypharmacy patterns. Further research on patients with co-morbidities or more severe conditions is needed, in order to improve knowledge of this issue.

[1]  J. Alda,et al.  Metabolic effects of second-generation antipsychotics in bipolar youth: comparison with other psychotic and nonpsychotic diagnoses. , 2010, Bipolar disorders.

[2]  H. Pincus,et al.  Concomitant pharmacotherapy among youths treated in routine psychiatric practice. , 2005, Journal of child and adolescent psychopharmacology.

[3]  R. Findling Open-label treatment of comorbid depression and attentional disorders with co-administration of serotonin reuptake inhibitors and psychostimulants in children, adolescents, and adults: a case series. , 1996, Journal of child and adolescent psychopharmacology.

[4]  S. Mitchell,et al.  Seizures induced by the combination treatment of methylphenidate and sertraline. , 2008 .

[5]  G. Perugi,et al.  Pharmacotherapy in Paediatric Obsessive-Compulsive Disorder , 2009, CNS drugs.

[6]  F. Lynch,et al.  Rising prevalence of antidepressants among US youths. , 2002, Pediatrics.

[7]  G. Carlson,et al.  Increased Rates of Bipolar Disorder Diagnoses Among U.S. Child, Adolescent, and Adult Inpatients, 1996–2004 , 2007, Biological Psychiatry.

[8]  Robert D Gibbons,et al.  The relationship between antidepressant prescription rates and rate of early adolescent suicide. , 2006, The American journal of psychiatry.

[9]  K. Merikangas,et al.  Lifetime prevalence of mental disorders in U.S. adolescents: results from the National Comorbidity Survey Replication--Adolescent Supplement (NCS-A). , 2010, Journal of the American Academy of Child and Adolescent Psychiatry.

[10]  E. Hunkeler,et al.  Trends in use of antidepressants, lithium, and anticonvulsants in Kaiser Permanente-insured youths, 1994-2003. , 2005, Journal of child and adolescent psychopharmacology.

[11]  Andrés Martin,et al.  Multiple psychotropic pharmacotherapy among child and adolescent enrollees in Connecticut Medicaid managed care. , 2003, Psychiatric services.

[12]  C. Correll,et al.  Endocrine and metabolic adverse effects of psychotropic medications in children and adolescents. , 2006, Journal of the American Academy of Child and Adolescent Psychiatry.

[13]  L. Greenhill,et al.  Pharmacotherapy of child and adolescent depression. , 2006, Child and adolescent psychiatric clinics of North America.

[14]  H. Tobi,et al.  Psychotropic co-medication among stimulant-treated children in The Netherlands. , 2005, Journal of child and adolescent psychopharmacology.

[15]  S. Cahill,et al.  Post-traumatic stress disorder and acute stress disorder I: their nature and assessment considerations. , 2005, Psychiatry (Edgmont (Pa. : Township)).

[16]  C. Arango,et al.  Características diferenciales de eficacia y tolerabilidad de los antipsicóticos de segunda generación en el tratamiento de trastornos psicóticos en niños y adolescentes , 2010 .

[17]  R. Johann-Liang,et al.  Off‐label prescribing patterns of antidepressants in children and adolescents , 2012, Pharmacoepidemiology and drug safety.

[18]  D. Clemow,et al.  Long-term weight gain in patients treated with open-label olanzapine in combination with fluoxetine for major depressive disorder. , 2005, The Journal of clinical psychiatry.

[19]  A. Awasthi,et al.  Acute myocardial infarction in a young male on methylphenidate, bupropion, and erythromycin. , 2005, Journal of child and adolescent psychopharmacology.

[20]  Combining Medications to Enhance Depression Outcomes (CO-MED): Acute and Long-Term Outcomes of a Single-Blind Randomized Study , 2012 .

[21]  A. Nardi,et al.  Body dysmorphic disorder treated with bupropion: cases report. , 2005, The Australian and New Zealand journal of psychiatry.

[22]  R. Aparasu,et al.  Extent of functional impairment in children and adolescents with depression , 2010, Current medical research and opinion.

[23]  R. Kowatch,et al.  Successful treatment of trichotillomania with olanzapine augmentation in an adolescent. , 2004, Journal of child and adolescent psychopharmacology.

[24]  H. Tobi,et al.  Antidepressant prevalence for youths: a multi‐national comparison , 2006, Pharmacoepidemiology and drug safety.

[25]  M. Weissman,et al.  National trends in the use of psychotropic medications by children. , 2002, Journal of the American Academy of Child and Adolescent Psychiatry.

[26]  C. Nemeroff,et al.  Impact of publicity concerning pediatric suicidality data on physician practice patterns in the United States. , 2007, Archives of general psychiatry.

[27]  M. A. Adeoye,et al.  Psychotropic Drug-Related Eosinophilia With Systemic Symptoms After Acute Caffeine Ingestion , 2011, Pediatrics.

[28]  R. Ferrell,et al.  Fluoxetine-related death in a child with cytochrome P-450 2D6 genetic deficiency. , 2000, Journal of child and adolescent psychopharmacology.

[29]  M. Strober,et al.  The pharmacotherapy of depressive illness in adolescence: II. Effects of lithium augmentation in nonresponders to imipramine. , 1992, Journal of the American Academy of Child and Adolescent Psychiatry.

[30]  M. Trivedi,et al.  Texas Children's Medication Algorithm Project: update from Texas Consensus Conference Panel on Medication Treatment of Childhood Major Depressive Disorder. , 2007, Journal of the American Academy of Child and Adolescent Psychiatry.

[31]  C. Essau Comorbidity of depressive disorders among adolescents in community and clinical settings , 2008, Psychiatry Research.

[32]  Michael J Wade,et al.  Current prescribing patterns in outpatient child and adolescent psychiatric practice in central New York. , 2005, Journal of child and adolescent psychopharmacology.

[33]  A. Josephson,et al.  Combined methylphenidate and imipramine complication. , 1995, Journal of the American Academy of Child and Adolescent Psychiatry.

[34]  Harold Alan Pincus,et al.  Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment: a meta-analysis of randomized controlled trials. , 2007, JAMA.

[35]  J. Biederman,et al.  Similarities in response to fluoxetine in the treatment of children and adolescents with obsessive-compulsive disorder. , 1995, Journal of the American Academy of Child and Adolescent Psychiatry.

[36]  J. Biederman,et al.  Atomoxetine alone or combined with fluoxetine for treating ADHD with comorbid depressive or anxiety symptoms. , 2005, Journal of the American Academy of Child and Adolescent Psychiatry.

[37]  Alan Apter,et al.  Psychiatric aspects of pediatric cancer. , 2003, Child and adolescent psychiatric clinics of North America.

[38]  R. Valuck,et al.  Persisting decline in depression treatment after FDA warnings. , 2009, Archives of general psychiatry.

[39]  P. Bentivoglio,et al.  Bupropion sustained release in adolescents with comorbid attention-deficit/hyperactivity disorder and depression. , 2001, Journal of the American Academy of Child and Adolescent Psychiatry.

[40]  M. Rynn,et al.  Efficacy of sertraline in the treatment of children and adolescents with major depressive disorder: two randomized controlled trials. , 2003, JAMA.

[41]  References , 1971 .

[42]  A. Mack,et al.  Clinical Response and Risk for Reported Suicidal Ideation and Suicide Attempts in Pediatric Antidepressant Treatment: A Meta-analysis of Randomized Controlled Trials , 2009 .

[43]  E. Storch,et al.  Clinical features associated with treatment-resistant pediatric obsessive-compulsive disorder. , 2008, Comprehensive psychiatry.

[44]  J. Micallef,et al.  Anxiolytics, hypnotics, and antidepressants dispensed to adolescents in a French region in 2002 , 2006, Pharmacoepidemiology and drug safety.

[45]  M. Lopez-Larson,et al.  Empirical Evidence for the Use of Lithium and Anticonvulsants in Children with Psychiatric Disorders , 2006, Harvard review of psychiatry.

[46]  K. J. Took,et al.  Enuresis with combined risperidone and SSRI use. , 1996, Journal of the American Academy of Child and Adolescent Psychiatry.

[47]  J. Bridge,et al.  Psychotropic Medication Changes, Polypharmacy, and the Risk of Early Readmission in Suicidal Adolescent Inpatients , 2009, The Annals of pharmacotherapy.

[48]  Golda S. Ginsburg,et al.  Remission and residual symptoms after short-term treatment in the Treatment of Adolescents with Depression Study (TADS). , 2006, Journal of the American Academy of Child and Adolescent Psychiatry.

[49]  Carmen Moreno,et al.  Efficacy and safety of second-generation antipsychotics in children and adolescents with psychotic and bipolar spectrum disorders: Comprehensive review of prospective head-to-head and placebo-controlled comparisons , 2011, European Neuropsychopharmacology.

[50]  John S. March,et al.  Practice Parameters for the Assessment and Treatment of Children and Adolescents With Obsessive-Compulsive Disorder , 1998 .

[51]  A. Dean,et al.  Psychotropic medication utilization in a child and adolescent mental health service. , 2006, Journal of child and adolescent psychopharmacology.

[52]  B. Birmaher,et al.  Treatment guidelines for children and adolescents with bipolar disorder. , 2005, Journal of the American Academy of Child and Adolescent Psychiatry.

[53]  M. Coskun,et al.  Tactile and visual hallucinations in a child with methylphenidate and fluoxetine combination. , 2008, Journal of clinical psychopharmacology.

[54]  M. Olfson,et al.  National trends in the treatment of attention deficit hyperactivity disorder. , 2003, The American journal of psychiatry.

[55]  N. Alessi,et al.  Buspirone augmentation of fluoxetine in a depressed child with obsessive-compulsive disorder. , 1991, The American journal of psychiatry.

[56]  R. Muñoz,et al.  American Psychiatric Association Practice Guidelines for the Treatment of Psychiatric Disorders: Compendium 2000 , 2002 .

[57]  Wilbur L. Smith,et al.  Case study: obsessive-compulsive disorder after severe traumatic brain injury in an adolescent. , 1995, Journal of the American Academy of Child and Adolescent Psychiatry.

[58]  W. Klykylo,et al.  Medication-induced seizures. , 1997, Journal of the American Academy of Child and Adolescent Psychiatry.

[59]  O. Oner,et al.  Psychopharmacology of pediatric obsessive-compulsive disorder: three case reports , 2008, Journal of psychopharmacology.

[60]  H. Akiskal,et al.  Bipolar co-morbidity in pediatric obsessive-compulsive disorder: clinical and treatment implications. , 2007, Journal of child and adolescent psychopharmacology.

[61]  T. Hyde,et al.  Neuroleptic-induced tardive dyskinesia. , 1996, The American journal of psychiatry.

[62]  R. McIntyre,et al.  Cardiovascular and Neurological Adverse Events Associated With Antidepressant Treatment in Children and Adolescents , 2009, Journal of child neurology.

[63]  N. Ghaziuddin,et al.  Myoclonus during prolonged treatment with sertraline in an adolescent patient. , 2001, Journal of child and adolescent psychopharmacology.

[64]  R. Raghavan,et al.  Use of multiple psychotropic medications among adolescents aging out of foster care. , 2008, Psychiatric services.

[65]  N. Crossley,et al.  Acceleration and augmentation of antidepressants with lithium for depressive disorders: two meta-analyses of randomized, placebo-controlled trials. , 2007, The Journal of clinical psychiatry.

[66]  D. Elkind Children and adolescents , 1970 .

[67]  J. Stockman Lifetime Prevalence of Mental Disorders in U.S. Adolescents: Results from the National Comorbidity Survey Replication–Adolescent Supplement (NCS-A) , 2012 .

[68]  H. Duggal,et al.  Treating selective serotonin reuptake inhibitor-induced behavioral activation with valproate. , 2003, Journal of child and adolescent psychopharmacology.

[69]  J. McKenzie,et al.  Selective serotonin reuptake inhibitors (SSRIs) for depressive disorders in children and adolescents. , 2007, The Cochrane database of systematic reviews.

[70]  W. A. Newman Dorland,et al.  Dorland's Illustrated Medical Dictionary , 1974 .

[71]  C. Debattista,et al.  Utility of Atypical Antipsychotics in the Treatment of Resistant Unipolar Depression , 2009, CNS drugs.

[72]  M. Davies,et al.  Psychosocial functioning in prepubertal major depressive disorders. I. Interpersonal relationships during the depressive episode. , 1985, Archives of general psychiatry.

[73]  Rebecca Tillman,et al.  Pharmacological and non-drug treatment of child bipolar I disorder during prospective eight-year follow-up. , 2010, Bipolar disorders.

[74]  D. Connor,et al.  Combined pharmacotherapy in children and adolescents in a residential treatment center. , 1997, Journal of the American Academy of Child and Adolescent Psychiatry.

[75]  D. Rosenberg,et al.  Risperidone augmentation of serotonin reuptake inhibitor treatment of pediatric obsessive compulsive disorder. , 1999, Journal of child and adolescent psychopharmacology.

[76]  O. Moghraby,et al.  Depression in children and young people: identification and management in primary, community and secondary care (NICE guideline CG28) , 2015, Archives of Disease in Childhood: Education & Practice Edition.

[77]  B. Vitiello An international perspective on pediatric psychopharmacology , 2008, International review of psychiatry.

[78]  Golda S. Ginsburg,et al.  Clinical characteristics of anxiety disordered youth. , 2010, Journal of anxiety disorders.

[79]  M. Bracken,et al.  A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder , 2006, Molecular Psychiatry.

[80]  Andrés Martin,et al.  Pediatric Psychopharmacology: Principles and Practice , 2002 .

[81]  J. Lijmer,et al.  Pharmacological treatment of psychotic depression Wijkstra , 2018 .

[82]  N. Halfon,et al.  Patterns of Comorbidity, Functioning, and Service Use for US Children With ADHD, 2007 , 2011, Pediatrics.

[83]  M. Nigro,et al.  Topiramate effectiveness in Prader-Willi syndrome. , 2003, Pediatric neurology.

[84]  S. Faraone,et al.  Effect of stimulants on height and weight: a review of the literature. , 2008, Journal of the American Academy of Child and Adolescent Psychiatry.

[85]  G. Gammon,et al.  Fluoxetine and methylphenidate in combination for treatment of attention deficit disorder and comorbid depressive disorder. , 1993, Journal of child and adolescent psychopharmacology.

[86]  E. Settle Antidepressant drugs: disturbing and potentially dangerous adverse effects. , 1998, The Journal of clinical psychiatry.

[87]  K. Ružić,et al.  Olanzapine treatment in anorexia nervosa: case report. , 2009, Psychiatria Danubina.

[88]  Erin S. Johns,et al.  Adjunctive quetiapine for treatment-resistant adolescent major depressive disorder: a case series. , 2005, Journal of child and adolescent psychopharmacology.

[89]  M. Olfson,et al.  National trends in the outpatient diagnosis and treatment of bipolar disorder in youth. , 2007, Archives of general psychiatry.

[90]  A. Sourander Combined psychopharmacological treatment among child and adolescent inpatients in Finland , 2004, European child & adolescent psychiatry.

[91]  L. Namerow,et al.  Citalopram for OCD and Tourette's syndrome. , 2001, Journal of the American Academy of Child and Adolescent Psychiatry.

[92]  N. Ryan,et al.  Lithium antidepressant augmentation in TCA-refractory depression in adolescents. , 1988, Journal of the American Academy of Child and Adolescent Psychiatry.

[93]  G. Glaeske,et al.  A three-country comparison of psychotropic medication prevalence in youth , 2008, Child and adolescent psychiatry and mental health.

[94]  D. Safer,et al.  Concomitant psychotropic medication for youths. , 2003, The American journal of psychiatry.

[95]  Z. Zadik,et al.  Decreased growth during therapy with selective serotonin reuptake inhibitors. , 2002, Archives of pediatrics & adolescent medicine.

[96]  F. Snoek,et al.  Depressive symptoms and unmet psychological needs of Dutch youth with type 1 diabetes: results of a web‐survey , 2011, Pediatric diabetes.

[97]  R. Bruun,et al.  Combined pharmacotherapy risk. , 1995, Journal of the American Academy of Child and Adolescent Psychiatry.

[98]  D. Safer,et al.  Treatment-emergent adverse events from selective serotonin reuptake inhibitors by age group: children versus adolescents. , 2006, Journal of child and adolescent psychopharmacology.

[99]  C. Arango,et al.  Differential characteristics of the efficacy and tolerability of second-generation antipsychotics in the treatment of psychotic disorders in children and adolescents , 2010 .

[100]  D. Stein,et al.  Combined pharmacotherapy for TS and OCD. , 1996, Journal of the American Academy of Child and Adolescent Psychiatry.

[101]  Y. Levkovitch,et al.  Can clozapine trigger OCD? , 1995, Journal of the American Academy of Child and Adolescent Psychiatry.

[102]  M. Olfson,et al.  National trends in child and adolescent psychotropic polypharmacy in office-based practice, 1996-2007. , 2010, Journal of the American Academy of Child and Adolescent Psychiatry.

[103]  R. Srivastava,et al.  Olanzapine augmentation of fluoxetine in trichotillomania: two cases. , 2005, The Australian and New Zealand journal of psychiatry.

[104]  M. Olfson,et al.  Relationship between antidepressant medication treatment and suicide in adolescents. , 2003, Archives of general psychiatry.

[105]  David Brent,et al.  Practice parameter for the assessment and treatment of children and adolescents with depressive disorders. , 2007, Journal of the American Academy of Child and Adolescent Psychiatry.

[106]  B. Vitiello,et al.  National trends in concomitant psychotropic medication with stimulants in pediatric visits: Practice versus knowledge , 2004, Journal of attention disorders.

[107]  J. Walkup Practice parameter on the use of psychotropic medication in children and adolescents. , 2009, Journal of the American Academy of Child and Adolescent Psychiatry.

[108]  E. Vieta,et al.  Treatment Options for Bipolar Depression: A Systematic Review of Randomized, Controlled Trials , 2010, Journal of clinical psychopharmacology.

[109]  M. Zonfrillo,et al.  Pediatric psychotropic polypharmacy. , 2005, Psychiatry (Edgmont (Pa. : Township)).

[110]  C. Varley,et al.  Pediatric Psychopharmacology: Principles and Practice , 2003 .

[111]  R. McIntyre,et al.  Polypharmacy in children and adolescents treated for major depressive disorder: a claims database study. , 2009, The Journal of clinical psychiatry.

[112]  J. Racoosin,et al.  Suicide Rates in Short-term Randomized Controlled Trials of Newer Antidepressants , 2006, Journal of clinical psychopharmacology.

[113]  A. Varan,et al.  Olanzapine treatment of an adolescent girl with anorexia nervosa , 2003, Human psychopharmacology.

[114]  M. Bonati,et al.  Randomised controlled trials of selective serotonin reuptake inhibitors in treating depression in children and adolescents: A systematic review and meta-analysis , 2008, European Neuropsychopharmacology.

[115]  James McCracken,et al.  Sequential pharmacotherapy for children with comorbid attention-deficit/hyperactivity and anxiety disorders. , 2005, Journal of the American Academy of Child and Adolescent Psychiatry.

[116]  R. Findling,et al.  A randomized, placebo-controlled trial of citalopram for the treatment of major depression in children and adolescents. , 2004, The American journal of psychiatry.

[117]  Dan J Stein,et al.  Selective serotonin reuptake inhibitors in children and adolescents. , 2002, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde.

[118]  R. Stafford,et al.  Depression treatment during outpatient visits by U.S. children and adolescents. , 2005, The Journal of adolescent health : official publication of the Society for Adolescent Medicine.

[119]  Ö. Özcan,et al.  Self-injury behavior in an adolescent with Wilson’s disease , 2009, European Child and Adolescent Psychiatry.

[120]  J. Crayton,et al.  Improvement of hallucinogen persisting perception disorder by treatment with a combination of fluoxetine and olanzapine: case report. , 2001, Journal of clinical psychopharmacology.

[121]  F. Keller,et al.  Psychotropic medication in children and adolescents in Germany: prevalence, indications, and psychopathological patterns. , 2009, Journal of child and adolescent psychopharmacology.

[122]  D. Sclar,et al.  Trends in prescriptions for antidepressant pharmacotherapy among US children and adolescents diagnosed with depression, 1990 through 2001: an assessment of accordance with treatment recommendations from the American Academy of Child and Adolescent Psychiatry. , 2009, Clinical therapeutics.

[123]  G. Walter,et al.  Lithium Augmentation of Venlafaxine in Adolescent Major Depression , 1998, The Australian and New Zealand journal of psychiatry.

[124]  B. Leventhal,et al.  Case series: Adderall augmentation of serotonin reuptake inhibitors in childhood-onset obsessive compulsive disorder. , 2002, Journal of child and adolescent psychopharmacology.

[125]  J. Newcorn,et al.  Atomoxetine treatment for pediatric patients with attention-deficit/hyperactivity disorder with comorbid anxiety disorder. , 2007, Journal of the American Academy of Child and Adolescent Psychiatry.

[126]  J. Biederman,et al.  A systematic chart review of the nature of psychiatric adverse events in children and adolescents treated with selective serotonin reuptake inhibitors. , 2003, Journal of child and adolescent psychopharmacology.

[127]  Jonathan C. Craig,et al.  Clinical trials in children. , 2015, British journal of clinical pharmacology.

[128]  P. Owens,et al.  Multiple psychotropic medication use for youths: a two-state comparison. , 2005, Journal of child and adolescent psychopharmacology.

[129]  G. Emslie,et al.  Review of the efficacy and safety of antidepressants in youth depression. , 2005, Journal of child psychology and psychiatry, and allied disciplines.

[130]  J. Stockman,et al.  Cognitive-behavior therapy, sertraline, and their combination for children and adolescents with obsessive-compulsive disorder: the Pediatric OCD Treatment Study (POTS) randomized controlled trial. , 2004, JAMA.

[131]  C. Pfanner,et al.  Aripiprazole Augmentation in 39 Adolescents With Medication-Resistant Obsessive-Compulsive Disorder , 2010, Journal of clinical psychopharmacology.

[132]  R. Bussing,et al.  Methamphetamine and fluoxetine treatment of a child with attention-deficit hyperactivity disorder and obsessive-compulsive disorder. , 1993, Journal of child and adolescent psychopharmacology.

[133]  D. Wiggins,et al.  Treatment of adolescent obsessive-compulsive disorder with a clomipramine-fluoxetine combination. , 1990, Psychopharmacology bulletin.

[134]  Daniela Berardi Statement of interest , 2002, Description Logics.

[135]  H. Tobi,et al.  Psychotropic medication in children: a study from the Netherlands. , 2001, Pediatrics.

[136]  L. Soorya,et al.  Divalproex versus placebo for the prevention of irritability associated with fluoxetine treatment in autism spectrum disorder. , 2006, Journal of clinical psychopharmacology.

[137]  C. Bell Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision: DSM-IV-TR Quick Reference to the Diagnostic Criteria from DSM-IV-TR , 2001 .

[138]  A. Vance,et al.  Single and Combined Psychotropic Medication Use in a Child and Adolescent Mental Health Service , 2004, The Australian and New Zealand journal of psychiatry.

[139]  S. Faraone,et al.  Therapeutic dilemmas in the pharmacotherapy of bipolar depression in the young. , 2000, Journal of child and adolescent psychopharmacology.

[140]  M. Kölch,et al.  Antidepressant use in children and adolescents in Germany. , 2006, Journal of child and adolescent psychopharmacology.

[141]  C. Good Adjunctive quetiapine targets self-harm behaviors in adolescent females with major depressive disorder. , 2006, Journal of child and adolescent psychopharmacology.

[142]  C. Roberts,et al.  Suicidal behaviour in youths with depression treated with new-generation antidepressants: meta-analysis. , 2006, The British journal of psychiatry : the journal of mental science.

[143]  P. Thomsen Risperidone augmentation in the treatment of severe adolescent OCD in SSRI-refractory cases: a case-series. , 2004, Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists.

[144]  Sarah A. Mustillo,et al.  Prevalence and development of psychiatric disorders in childhood and adolescence. , 2003, Archives of general psychiatry.

[145]  M. Chassin,et al.  Can experts agree when to hospitalize adolescents? , 1995, Journal of the American Academy of Child and Adolescent Psychiatry.

[146]  D. Coghill,et al.  Adverse Effects of Pharmacotherapies for Attention-Deficit Hyperactivity Disorder , 2008, CNS drugs.

[147]  H. Mikkelsen,et al.  The addition of buspirone to SSRI in the treatment of adolescent obsessive-compulsive disorder. A study of six cases , 1999, European Child & Adolescent Psychiatry.

[148]  P. Russell,et al.  Predictive factors for polypharmacy among child and adolescent psychiatry inpatients , 2006, Clinical practice and epidemiology in mental health : CP & EMH.

[149]  P. Kendall,et al.  Prevalence and co-morbidity among anxiety disorders in a national cohort of psychiatrically referred children and adolescents. , 2010, Journal of anxiety disorders.

[150]  H. Rittmannsberger The use of drug monotherapy in psychiatric inpatient treatment , 2002, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[151]  C. Ernest,et al.  Effect of Potent CYP2D6 Inhibition by Paroxetine on Atomoxetine Pharmacokinetics , 2002, Journal of clinical pharmacology.

[152]  J. Calabrese,et al.  A pilot pharmacotherapy trial for depressed youths at high genetic risk for bipolarity. , 2008, Journal of child and adolescent psychopharmacology.

[153]  J. Rushton,et al.  Pediatric stimulant and selective serotonin reuptake inhibitor prescription trends: 1992 to 1998. , 2001, Archives of pediatrics & adolescent medicine.

[154]  M. Keshavan,et al.  Combination treatment with clomipramine and selective serotonin reuptake inhibitors for obsessive-compulsive disorder in children and adolescents. , 1998, Journal of child and adolescent psychopharmacology.

[155]  J. Swanson,et al.  The Texas Children's Medication Algorithm Project: revision of the algorithm for pharmacotherapy of attention-deficit/hyperactivity disorder. , 2006, Journal of the American Academy of Child and Adolescent Psychiatry.